CAN-3110

AXP000087.1 · Oncolytic virus

Platform
HSV-1 (strain F, nestin-promoter ICP34.5)
Originator
Brigham and Women's Hospital (E. Antonio Chiocca)
Sponsor
Candel Therapeutics

Names

NameTypeSource
CAN-3110preferred name, codecurator, ctgov
rQNestin34.5v.2codectgov
rQNestin ambiguoussynonymctgov

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
F
Replication
conditionally replicating
Modifications
one ICP34.5 copy re-inserted under the nestin promoter; UL39 (ICP6) disrupted by a GFP cassette
Transgenes
GFP
Route
intratumoral, intracerebral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03152318A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Active not recruitingPhase 12017-07-182027-0162Anaplastic Oligodendroglioma of Brain (Diagnosis); Astrocytoma; Brain Cancer; Brain Tumor; Ependymoma; Ganglioglioma; Glioblastoma; Glioblastoma Multiforme; Glioma; Malignant Astrocytoma; Malignant Glioma of Brain; Mixed Oligo-Astrocytoma; Oligodendroglioma; Pylocytic/Pylomyxoid Astrocytoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41679299Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial.Cell2026cited by trial NCT03152318
PMID 38853689Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.Neuro-oncology2024cited by trial NCT03152318
PMID 37853118Clinical trial links oncolytic immunoactivation to survival in glioblastoma.Nature2023cited by trial NCT03152318
PMID 35022322NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research2022cited by trial NCT03152318
PMID 32373649Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene.Molecular therapy. Methods & clinical development2020cited by trial NCT03152318

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41411618Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis.Cancer research2026name in abstract: CAN-3110
PMID 41506791CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation.Journal for immunotherapy of cancer2026name in abstract: CAN-3110
PMID 41689740Clinical outcomes in recurrent glioblastoma with oncolytic virotherapy: a review.Molecular biology reports2026name in abstract: CAN-3110
PMID 42310302IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.Nature communications2026name in abstract: rQNestin34.5v.2
PMID 42732006Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.Oncogene2026name in abstract: CAN-3110
PMID 41061048Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.Science translational medicine2025name in abstract: CAN-3110
PMID 38806994A viral attack on brain tumors: the potential of oncolytic virus therapy.Journal of neurovirology2024name in abstract: rQNestin34.5v.2
PMID 34004331Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.Seminars in cancer biology2022name in abstract: rQNestin34.5v.2

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P01CA163205Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapyBRIGHAM AND WOMEN'S HOSPITALKAUR, BALVEEN2023–2026name in abstract: rQNestin34.5v.2
U01NS061811Preclinical Toxicity Evaluation of a Potent Oncolytic VirusBRIGHAM AND WOMEN'S HOSPITALCHIOCCA, E. ANTONIO2008–2012name in abstract: rQNestin34.5v.2

Notes

rQNestin34.5v.2: ICP34.5 restored but placed under the nestin promoter, so replication is limited to nestin-expressing glioma cells. Phase 1 with cyclophosphamide (NCT03152318); results in Nature 2023.

How to cite

CAN-3110 (AXP000087.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000087.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.